Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1365-1372

  Shah, Chirag A ^a   Lowe, Kimberly A ^b,d   Paley, Pamela ^c   Wallace, Erin ^b   Anderson, Garnet L ^b   McIntosh, Martin W ^b   Andersen, M Robyn ^b   Scholler, Nathalie ^e   Bergan, Lindsay A ^b   Thorpe, Jason D ^b   Urban, Nicole ^b   Drescher, Charles W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Pacific Gynecology Specialists   (United States)

^d EXPONENT INC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEIN; HUMAN EPIDIDYMIS PROTEIN 4; MESOTHELIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PEDIGREE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AREA UNDER CURVE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 66549097456     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1034     Document Type: Article

References (31)

1. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-281 (Pubitemid 43096594)
2. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-1246 (Pubitemid 47620999)
3. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-453 (Pubitemid 43166134)
4. Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 2006;26:4721-4728
5. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-277 (Pubitemid 41502830)
6. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006;12:827-831 (Pubitemid 43259864)
7. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15. (Pubitemid 39286271)
8. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-2169 (Pubitemid 40490123)
9. Scholler N, Crawford M, Sato A, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006;12:2117-2124
10. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-385 (Pubitemid 29446174)
11. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-3700 (Pubitemid 36793054)
12. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816 (Pubitemid 41798292)
13. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710 (Pubitemid 32203724)
14. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130 (Pubitemid 36530000)
15. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
16. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-1327 (Pubitemid 41079847)
17. Levine DA, Federici MG, Reuter VE, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol 2002;85:431-434 (Pubitemid 34651880)
18. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-411
19. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-2481 (Pubitemid 38445709)
20. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265 (Pubitemid 30246777)
21. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000. (Pubitemid 34814728)
22. Scholler N, Lowe KA, Bergan L, et al. Use of yeast-secreted in vivo biotinylated recombinant antibodies (biobodies) in bead-based ELISA. Clin Cancer Res 2008;14:2647-2655
23. Bergan L, Gross JA, Nevin B, Urban N, Scholler N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin- dependent cell attachment. Cancer Lett 2007;255:263-274 (Pubitemid 47268642)
24. Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology 2005;16:598-603. (Pubitemid 41233612)
25. Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol 1975;12:387-415.
26. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845 (Pubitemid 18243017)
27. Stata Statistical Software. College Station, TX: StataCorp LP.
28. Menon U, Burnell M, Sharma A, et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007;14:462-467
29. Skates S, Horick N, Finkelstein D, Lu K, editors. Prospective multicenter ovarian cancer screening trial for women at high risk: Preliminary results from the first 2,200 women. Risk Prediction Workshop; 2004 May 20-21; Washington D.C.
30. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489-493 (Pubitemid 32701635)
31. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2480-2487